New drug shows promise for rare blistering skin condition
NCT ID NCT02226146
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a drug called bertilimumab in 11 adults aged 60 and older with newly diagnosed bullous pemphigoid, a condition that causes painful blisters. The main goals were to check safety and see if the drug helps control the disease. While results may show some benefit, this is not a cure, and patients typically need ongoing treatment to manage the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEMPHIGOID, BULLOUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Iowa City, Iowa, United States
-
Research Site
Buffalo, New York, United States
-
Research Site
New York, New York, United States
-
Research Site
Durham, North Carolina, United States
-
Research Site
Cleveland, Ohio, 10900, United States
-
Research Site
Salt Lake City, Utah, United States
-
Research Site
Ramat Gan, 5262100, Israel
-
Research Site
Tel Aviv, 64239, Israel